Talking about what others are afraid to say
The pharma world has spent the last couple of years acting like GLP-1’s can’t lose. There are tons of Americans with obesity. Drugs like Wegovy and Zepbound cause dramatic weight …
Why GLP-1 Usage May Decline Despite Demand Read More
There is something surreal about watching television and seeing an advertisement for a cancer drug. A patient is walking on a beach. A family is laughing around a dinner table. …
The Absurdity of Advertising Oncology Drugs Read More
If you’ve watched TV any time in the last 25 years, you know the formula: warm lighting, a golden retriever running through a field, a voiceover listing side effects so …
The Pharma Ad You Grew Up With Is Probably Dying. Here’s What’s Replacing It. Read More
Drug companies have poured billions of dollars into precision medicine research and development. They’re discovering mutations that help us treat cancers more precisely and creating therapies that target specific patient …
Cancer doesn’t pause while the paperwork’s in progress. Read More
Dave Ricks, Eli Lilly’s CEO, can share a stat Wall Street will enjoy hearing. Around a third of patients initiating oral GLP-1s are choosing Lilly’s product, Foundayo. According to CNBC, …
Lilly Is Winning the GLP-1 Pill Race. But Can It Keep Patients on the Drug? Read More
You used to be able to argue about vaccines in an almost hypothetical sense. Mandates, pharma, the government, and personal choice were all fair game to talk about. Not so …
Enough of the Vaccine Skepticism. People Are Paying the Price. Read More
Drug makers are scrambling to produce the next wave of obesity drugs. Just one problem. The payers expected to pay are pushing back. For years, the obesity drug conversation has …
The Weight-Loss Drug Pipeline Has a Problem: Who Will Pay? Read More
For years, pharma companies have spent millions building and rebuilding websites that too often feel designed to satisfy internal stakeholders rather than the people who actually use them. Brand teams …
Pharma Websites: How to make them relevant again Read More